Fig. 9

Enhanced attenuation of OVA-specific IgE and OVA-induced IL-4 production (a, c) but not of IgG or OVA-induced IL-2 production (b, d) in groups of 5 BALB/c mice immunized with OVA in alum and receiving combined anti-C3H and anti–anti-C3H Ig as in Fig. 2, and in addition receiving further infusions of rat mAbs directed to TNFSFR25 [25, 26]. A control group, Control C1, received no combined immune Ig/anti-idiotype Ig treatment. Other groups of mice received iv infusions of 10 μg rat Ig prepared from a control hybridoma supernatant (2D6) or similar quantities of Ig purified from anti-TNFSFR25 hybridomas (2D4, 7C3) on the last 3 weeks of treatment with the anti-C3H and anti–anti-C3H Ig. A control group, control C2, received no iv infusions. Data show mean ± SD of IgE and IgG levels in serum, and IL-2/IL-4 in 72 h cultures of OVA-stimulated cells, of mice receiving a final boost of OVA in alum 7 days after the final immunoglobulin treatment and sacrificed 10 days later. *p < 0.05 compared with Control C1; **p < 0.05 compared with Control C2 and group with 2D6